{"title":"基于网络药理学的Tilianin抗心肌梗死靶点及机制预测与实验验证","authors":"Xiaojing Li, Ning Li, Xiaoyi Yang, Cheng Zeng","doi":"10.37290/ctnr2641-452x.21:150-158","DOIUrl":null,"url":null,"abstract":"Tilianin is a flavonoid glycoside with potential applications in the prevention and treatment of myocardial infarction, but its specific targets and pharmacological mechanisms are unclear. Therefore, in this study, a reverse screening and molecular docking approach was used to predict the pharmacological targets and mechanisms of tilianin on myocardial infarction based on network pharmacology and experimental validation. Firstly, we screened various databases to obtain potential core targets of tilianin. Secondly, we used protein–protein interaction, gene ontology, Kyoto Encyclopedia of Genes and Genomes, and ClueGO to correlate the key targets before molecular docking of new target genes. Finally, the gene expression of tilianin in HL-1 cells was experimentally validated with quantitative real-time polymerase chain reaction and immunofluorescence. The result showed that tilianin may significantly modulate pro-inflammatory effects in the tumor necrosis factor-α signaling pathway, which activates and regulates various cellular activities. Molecular docking revealed that protein kinase B1, proto-oncogene cellular sarcoma, tumor necrosis factor-α, matrix metalloproteinase-9, nitric oxide synthetase 2, mitogen-activated protein kinase 14 and phosphatase and tensin homolog-induced kinase 1 may be the key targets for the systematic regulatory effect of tilianin against myocardial infarction. Finally, quantitative real-time polymerase chain reaction and immunofluorescence results showed that tilianin significantly influences the expression of the key genes in myocardial infarction. Using network bioinformatic analysis, molecular docking techniques, and experimental validation, we predicted and preliminarily validated potential target sites for tilianin. These findings provide a new perspective for further exploration of the mechanism of action of tilianin in myocardial infarction therapy. Meanwhile, this study provides an objective basis for further experimental studies in the future.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Network Pharmacology-Based Prediction and Experimental Validation of the Targets and Mechanism of Tilianin Action Against Myocardial Infarction\",\"authors\":\"Xiaojing Li, Ning Li, Xiaoyi Yang, Cheng Zeng\",\"doi\":\"10.37290/ctnr2641-452x.21:150-158\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tilianin is a flavonoid glycoside with potential applications in the prevention and treatment of myocardial infarction, but its specific targets and pharmacological mechanisms are unclear. Therefore, in this study, a reverse screening and molecular docking approach was used to predict the pharmacological targets and mechanisms of tilianin on myocardial infarction based on network pharmacology and experimental validation. Firstly, we screened various databases to obtain potential core targets of tilianin. Secondly, we used protein–protein interaction, gene ontology, Kyoto Encyclopedia of Genes and Genomes, and ClueGO to correlate the key targets before molecular docking of new target genes. Finally, the gene expression of tilianin in HL-1 cells was experimentally validated with quantitative real-time polymerase chain reaction and immunofluorescence. The result showed that tilianin may significantly modulate pro-inflammatory effects in the tumor necrosis factor-α signaling pathway, which activates and regulates various cellular activities. Molecular docking revealed that protein kinase B1, proto-oncogene cellular sarcoma, tumor necrosis factor-α, matrix metalloproteinase-9, nitric oxide synthetase 2, mitogen-activated protein kinase 14 and phosphatase and tensin homolog-induced kinase 1 may be the key targets for the systematic regulatory effect of tilianin against myocardial infarction. Finally, quantitative real-time polymerase chain reaction and immunofluorescence results showed that tilianin significantly influences the expression of the key genes in myocardial infarction. Using network bioinformatic analysis, molecular docking techniques, and experimental validation, we predicted and preliminarily validated potential target sites for tilianin. These findings provide a new perspective for further exploration of the mechanism of action of tilianin in myocardial infarction therapy. Meanwhile, this study provides an objective basis for further experimental studies in the future.\",\"PeriodicalId\":10976,\"journal\":{\"name\":\"Current Topics in Nutraceutical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Topics in Nutraceutical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.37290/ctnr2641-452x.21:150-158\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Topics in Nutraceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.37290/ctnr2641-452x.21:150-158","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Network Pharmacology-Based Prediction and Experimental Validation of the Targets and Mechanism of Tilianin Action Against Myocardial Infarction
Tilianin is a flavonoid glycoside with potential applications in the prevention and treatment of myocardial infarction, but its specific targets and pharmacological mechanisms are unclear. Therefore, in this study, a reverse screening and molecular docking approach was used to predict the pharmacological targets and mechanisms of tilianin on myocardial infarction based on network pharmacology and experimental validation. Firstly, we screened various databases to obtain potential core targets of tilianin. Secondly, we used protein–protein interaction, gene ontology, Kyoto Encyclopedia of Genes and Genomes, and ClueGO to correlate the key targets before molecular docking of new target genes. Finally, the gene expression of tilianin in HL-1 cells was experimentally validated with quantitative real-time polymerase chain reaction and immunofluorescence. The result showed that tilianin may significantly modulate pro-inflammatory effects in the tumor necrosis factor-α signaling pathway, which activates and regulates various cellular activities. Molecular docking revealed that protein kinase B1, proto-oncogene cellular sarcoma, tumor necrosis factor-α, matrix metalloproteinase-9, nitric oxide synthetase 2, mitogen-activated protein kinase 14 and phosphatase and tensin homolog-induced kinase 1 may be the key targets for the systematic regulatory effect of tilianin against myocardial infarction. Finally, quantitative real-time polymerase chain reaction and immunofluorescence results showed that tilianin significantly influences the expression of the key genes in myocardial infarction. Using network bioinformatic analysis, molecular docking techniques, and experimental validation, we predicted and preliminarily validated potential target sites for tilianin. These findings provide a new perspective for further exploration of the mechanism of action of tilianin in myocardial infarction therapy. Meanwhile, this study provides an objective basis for further experimental studies in the future.
期刊介绍:
Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products.
To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine.
The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.